Mendoza M, Garcia‐Manau P, Arévalo S, et al. - Researchers conducted a prospective cohort study at Vall d'Hebron University Hospital (Barcelona) from October 2015 to September 2017 in order to compare the capacity of the first‐trimester combined screening for preeclampsia (PE) to prognosticate early‐onset and preterm PE when biomarkers were determined before or after 11 weeks of gestation. Assessment of maternal serum concentration of pregnancy‐associated plasma protein‐A (PAPP‐A) and placental growth factor (PlGF) was done from the first‐trimester routine blood test (at 8+0 to 13+6 weeks). Among the 2,641 women, assessment of biomarkers was done at < 11 WG in 1,675 (63.4%) and at ≥ 11 WG in 966 (36.6%). PE developed in 90 of these women (3.41%), including 11 cases (0.42%) with early‐onset PE and 30 (1.14%) with preterm PE. Similar prediction was done for early‐onset and preterm PE in correlation with assessment of biomarkers before vs after 11 weeks. This indicates the utility of a two‐step approach for PE risk assessment which allows immediate risk calculation at the moment of the first‐trimester scan.